Amarillo Biosciences Inc.
Description Amarillo Biosciences, Inc. engages in the development of biologics for the treatment of human and animal diseases. It owns or licenses five issued patents related to the low-dose oral delivery of interferon and one issued patent on its dietary supplement, Maxisal. The company develops low-dose oral interferon alpha, which is in the Phase II clinical trial for the treatment of influenza, hepatitis C, chronic cough, and opportunistic infections in patients who are HIV positive. It has strategic alliances with Intas Pharmaceuticals Ltd.; Hayashibara Biochemical Laboratories, Inc.; Bumimedic (Malaysia) Sdn. Bhd; CytoPharm, Inc.; and Cadila Healthcare. Amarillo Biosciences, Inc. was founded in 1984 and is based in Amarillo, Texas. To view the detailed information, you need to SUBSCRIBE with us. |
 |